Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17268630 | 0.78 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL774246 | 0.74 | — | — | |
| SCHEMBL14681224 | 0.71 | — | — | |
| SCHEMBL14675199 | 0.70 | CYP2C19 (0.33) | CYP2C19POLBBLMATMACHE | |
| SCHEMBL767191 | 0.70 | NAAA (0.40) | CYP2C19POLBBLMATM | |
| SCHEMBL2965145 | 0.69 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL16965084 | 0.69 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL767174 | 0.68 | ALDH1A1 (0.59) | CYP2C19POLBBLMATM | |
| SCHEMBL20299385 | 0.68 | PRKCA (0.38) | CYP2C19NPSR1POLBBLMATM | |
| SCHEMBL14232056 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013017469-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013017469-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20120071640-A1 | Sulfurizing reagents and their use for oligonucleotides synthesis | GIRINDUS AMERICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071640-A1 | Sulfurizing reagents and their use for oligonucleotides synthesis | GIRINDUS AMERICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071640-A1 | Sulfurizing reagents and their use for oligonucleotides synthesis | GIRINDUS AMERICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2382227-A1 | SULFURIZING REAGENTS AND THEIR USE FOR OLIGONUCLEOTIDES SYNTHESIS | Girindus America, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072831-A1 | SULFURIZING REAGENTS AND THEIR USE FOR OLIGONUCLEOTIDES SYNTHESIS | GIRINDUS AMERICA, INC (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072831-A1 | SULFURIZING REAGENTS AND THEIR USE FOR OLIGONUCLEOTIDES SYNTHESIS | GIRINDUS AMERICA, INC (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071640-A1 | Sulfurizing reagents and their use for oligonucleotides synthesis | RRM1, SRRT, NSUN2 | CHRNB2 1878/4885CHRNA4 1910/4885CHRM2 3383/4885 |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | OR10J3, RPS8, NSUN2 | CHRNB2 1639/4885CHRNA4 848/4885CHRM2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.